Advanced Search

Primary Bone Marrow CD34+ Cells, Normal, Human (ATCC® PCS-800-012™)

Organism: Homo sapiens, human  /  Tissue: Bone  /  Cell Type: Hematopoietic stem

Organism Homo sapiens, human
Tissue Bone
Cell Type Hematopoietic stem
Morphology spherical; variable after culturing
Growth Properties suspension; variable after culturing
Biosafety Level 1  [These primary cells are not known to harbor an agent recognized to cause disease in healthy adult humans. Handle as a potentially biohazardous material under at least Biosafety Level 1 containment. Cells derived from primate lymphoid tissue may fall under the regulations of 29 CFR 1910.1030 Bloodborne Pathogens. 

ATCC recommends that appropriate safety procedures be used when handling all primary cells and cell lines, especially those derived from human or other primate material. Detailed discussions of laboratory safety procedures are provided in Laboratory Safety: Principles and Practice, 2nd ed. (ASM Press, Washington, DC) (Fleming et al., 1995) and Caputo, J.L. Biosafety procedures in cell culture. (1988) J. Tissue Culture Methods 11:223. Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS Publication No. (CDC) 93-8395. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online at http://www.cdc.gov/biosafety/publications/bmbl5/index.htm.] 

Human Material Precaution 
All tissues used for isolation are obtained under informed consent and conform to HIPAA standards to protect the privacy of the donor’s personal health information. It is best to use caution when handling any human cells. We recommend that all human cells be accorded the same level of biosafety consideration as cells known to carry HIV. With infectious virus assays or viral antigen assays, even a negative test result may leave open the possible existence of a latent viral genome.


Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease normal
Age lot specific
Gender lot specific
Ethnicity lot specific
Applications Applications for use include the study of stem cell biology, hematology, transplantation, and oncology.
Product Format frozen 0.50 mL
Storage Conditions liquid nitrogen vapor phase
Comments

Cluster of differentiation 34 (CD34) is a sialomucin-family protein that is expressed on the surface of blood, endothelial, and bone marrow-derived progenitor cells. While the functions of CD34 are not well understood, there is evidence that the protein is involved in maintaining progenitor cells in an undifferentiated state.

The ATCC maintains CD34+ bone marrow-derived and CD34+ cord blood-derived cells which may be used to support physiologically relevant research in regenerative medicine, transplant studies, stem cell biology, hematology, and oncology. These pluripotent stem cells are isolated by immunomagnetic positive selection. In addition, the ATCC Cell Systems Laboratory has conducted in-depth characterization of the cells including differentiation into all three cell lineages.
Complete Growth Medium CD34+ cells have a limited lifespan in culture and should only be thawed immediately prior to their intended use. ATCC does not recommend maintaining CD34+ cells in culture in the absence of application-specific growth factors.
Volume 0.50 mL
Cells per Vial One vial contains a minimum of 5 x 105  viable cells.
Viral Testing
Hepatitis B: Negative
Hepatitis C: Negative
HIV(I/II): Negative
HTLV(I/II): Negative
WNV: Negative
Trypanasome: Negative
Viability ≥ 70% when thawed from cryopreservation
C of A
Certificate of Analysis
Certificate of Analysis
Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
SDS
SDS
FAQs
  1. Isolation of ATCC® PCS-800-012 ™, Human Primary Bone Marrow CD34+ cells
    CD34+ cells are isolated using positive immunomagnetic cell separation from the bone marrow.
    Date Updated: 8/27/2014
  2. Purity of ATCC® PCS-800-012, Human Primary Bone Marrow CD34+ cells
    ATCC CD34+ cells have been tested to have a purity of over 90% as measured by flow cytometry with a monoclonal CD34 antibody.
    Date Updated: 8/27/2014
  3. Cryopreservative used with PCS-800-012
    ATCC CD34+ cells are cryopreserved in CryoStor® CS10 Freeze Medium from BioLife Solutions.
    Date Updated: 8/27/2014
  4. Long term culture of ATCC® PCS-800-012
    CD34+ cells have a limited lifespan in culture and should only be thawed immediately prior to their intended use. ATCC does not recommend maintaining CD34+ cells in culture in the absence of appl...
    Date Updated: 8/27/2014
  5. Post-thaw yield and viability of ATCC® PCS-800-012 ™ Human Primary Bone Marrow CD34+ cells

    We recommend the following thawing procedure:


    Date Updated: 1/12/2017
  6. CD34 positive primary cells from non-normal donors

    No, at this time ATCC does not offer CD34+ cells from non-normal donors. The ATCC® PCS-800-012 ™, Human Primary Bone Marrow CD34+ cells are from normal donor sources.


    Date Updated: 8/27/2014
References

Mahalingaiah PK, et al. An In Vitro Model of Hematotoxicity: Differentiation of Bone Marrow-Derived Stem/Progenitor Cells into Hematopoietic Lineages and Evaluation of Lineage-Specific Hematotoxicity. Current Protocols Toxicol 76(1), 2018. DOI: 10.1002/cptx.45

Li Z, et al. Mesenchymal stem cells promote endothelial progenitor cell migration, vascularization, and bone repair in tissue-engineered constructs via activating CXCR2-Src-PKL/Vav2-Rac1. FASEB 32(4):2197-2211, 2018. PubMed: 29229683

Nicolae CM, et al. NFkB regulates p21 expression and controls DNA damage-induced leukemic differentiation. Oncogene 2018. PubMed: 29622796

Yivgi-Ohana N, Halavee U. Mammalian cells enriched with functional mitochondria. Patent Application Publication Pub. No.: US 2018/0030413 A1, 2018.

Wang B, Zeiner G. Smart CAR Devices and DE CAR Polypeptides for Treating Disease and Methods for Enhancing Immune Responses. Patent Application Publication Pub. No.: US 2017/0157176 A1, 2017.